Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was well tolerated in post-endocrine...

Related Keywords

Canada ,Sapporo ,Hokkaido ,Japan ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Spain ,Madrid ,America ,Daiichi Sankyo ,End Results Program ,Astrazeneca ,European Society For Medical Oncology ,Sapporo Medical University ,Merck Co Inc ,National Cancer Institute ,Presidential Symposium ,European Society ,Medical Oncology ,North America ,South America ,Rare Diseases ,Cancer Statistics ,Mortality Worldwide ,End Results ,Accessed October ,Epidermal Growth Factor Receptor ,Mol Biol ,Overall Survival ,Plus Endocrine Therapy ,Therapy Alone ,Advanced Hormone Receptor ,Breast Cancer ,Emerging Therapeutic ,Clin Cancer ,Cell Surface Antigen ,Cancer Res ,Markets ,